Introduction
From an epigenetic perspective, the study of tumor suppressor genes has become notably relevant due to the fact that deregulation of these genes is associated with tumorigenic processes (Jones and Baylin, 2007) . In particular, 70% of human genes are linked to promoters that contain CpG islands that are the target of abnormal epigenetic events (Antequera, 2003; Issa, 2004) . On the basis of recent proposals, the CpG island can be cataloged as a low, intermediate or high CpG island (Weber et al., 2007) . High CpG islands have been linked to housekeeping gene promoters that are normally unmethylated, whereas low CpG islands are associated with tissue-specific gene promoters that can be methylated, apparently without affecting their regulatory potential. This classification demands novel interpretations depending on the nature of the CpG island, as a distinct combination of epigenetic silencing mechanisms can now be expected (Weber et al., 2007; Kondo et al., 2008; Meissner et al., 2008) . For example, the high CpG island promoters are more frequently silenced by DNA methylation in abnormal conditions, even though histone repressive marks, such as H3 lysine 9 trimethylation (H3K9me3), can also be incorporated (McGarvey et al., 2006; Kondo et al., 2008) . In contrast, intermediate and low CpG islands can be silenced by covalent histone modifications such as H3 lysine 27 trimethylation (H3K27me3) (Kondo et al., 2008) , and not by DNA methylation. Thus, H3K27me3 and DNA methylation can exert an effect independently, and their aberrant promoter targets seem to be defined by the CpG content (Weber et al., 2007; Kondo et al., 2008) .
In this study we assessed the mechanisms of epigenetic silencing of the human p53 tumor suppressor gene in cancer cells. On the basis of recently established definitions, we consider the human p53 promoter to correspond to an ICP island that is apparently not frequently silenced by DNA methylation (Pogribny et al., 2000; Kang et al., 2001; Amatya et al., 2005) . We hypothesize that different classes of CpG islands might be regulated differently, not only at the level of DNA methylation and/or Polycomb family members but also in terms of selective and differential use of transcription factors. In accordance, in this study we address whether different kinds of CpG island promoters are epigenetically regulated by alternative mechanisms (De La Rosa-Vela´zquez et al., 2007) . We found that the multifunctional CCCTC-binding site factor (CTCF) is involved in p53 epigenetic regulation by harboring an open chromatin configuration. Remarkably, p53 gene promoter epigenetic silencing is not dependent on DNA methylation. Instead, repressive histone modifications are enriched and represent the main cause of silencing in the presence of reduced levels of CTCF. We propose a model in which CTCF can overcome epigenetic silencing not only by counteracting DNA methylation (as in the case of Rb and other tumor suppressor gene promoters) but also by blocking the incorporation of repressive covalent histone modifications.
Results
Gene expression and epigenetic profiles of the human p53 gene in epithelial cell lines On the basis of predicted differences in p53 gene expression in transformed epithelial cell lines, we decided to explore these differences and correlate them with their chromatin structural status with the aim of finding a model system for p53 epigenetic silencing. We first characterized the expression profile of the p53 gene using reverse transcriptase PCR (RT-PCR) in SW480, HeLa, Kb epithelial cell lines and in a primary culture of human fibroblasts obtained from neonatal foreskin (Figure 1a ). We found that the colorectal adenocarcinoma SW480 cells show the highest levels of expression, followed by HeLa and Kb cell lines, when compared with the primary culture of normal fibroblasts.
To analyze the relationship between p53 gene expression and its epigenetic entourage, we next evaluated the DNA methylation status of the p53 gene promoter by the sodium bisulfite conversion assay (Figure 1b) . No DNA methylation was detected at the p53 gene core promoter in any of the cell lines studied. We then evaluated the patterns of histone covalent modifications over the p53 gene promoter. We found that the histone H3K4me2 modification and the polyacetylation of histone H3 and H4 are drastically enriched in SW480 cells (Figure 1c) . To corroborate the in situ chromatin status of the promoter we performed a restriction enzyme accessibility assay (Escamilla-Del-Arenal and Recillas-Targa, 2008) (Figure 1d ). The results of these experiments are in accordance with the previous assays, and they show that the p53 gene promoter has an open chromatin conformation in the SW480 cell line, whereas the HeLa and Kb cell lines show a more compacted chromatin structure (Figure 1d ). Taken together, these results suggest that p53 gene expression regulation in normal and cancer cells can be influenced not only by ubiquitous or stage-specific transcription factors, but also by the chromatin configuration of its promoter.
Epigenetic silencing model for the p53 gene promoter in glioma cell lines We next decided to explore other cell types that have been reported to show DNA methylation over the p53 gene promoter (Amatya et al., 2005) . We first evaluated p53 protein abundance by immunofluorescence in T98G and U87MG glioma cell lines (Figure 2a ). The absence of p53 in these two glioma cell lines was confirmed (Figures 2a and b) . To evaluate their DNA methylation status, cells were treated with the methylation inhibitor, 5-aza-2'-deoxycytidine, for 72 h. Immunofluorescence, western blotting and quantitative RT-PCR assays showed a marginal reactivation of p53 expression (Figure 2 ), most notably in the treated T98G cells. Surprisingly, when we performed a sodium bisulfite conversion assay and sequencing using primers located in the core promoter we were not able to detect any DNA methylation (Figure 3a , site 4, and Supplementary  Figure 1 ). On the basis of such unexpected result we decided to survey the DNA methylation status of a larger genomic area in T98G cells (Figure 3a) . In all, seven DNA sub-fragments were analyzed using sodium bisulfite conversion and sequencing, including upstream genomic sequences in relation to the p53 transcription start site and CpG-rich intronic sequences (Figure3a and Supplementary Figure 1) . As positive controls we tested two unrelated genomic sequences known to possess different levels of DNA methylation and in vitro methylated genomic DNA (Supplementary Figure 2) . One more time, this extended analysis did not allow the identification of any DNA methylation. These results confirm on one side that p53 gene expression can be reactivated using the DNA methylation inhibitor in glioma cell lines, and on the other, that the core promoter and surrounding sequences in a range of 3 kb are hypomethylated. Therefore, these two glioma cell lines may represent a cancer cell context in which p53 epigenetic silencing can be studied, and whether the presence of CTCF contributes to such a process can also be explored.
In vitro and in vivo binding of CTCF to the upstream region of the human p53 gene promoter On the basis of our previous report suggesting that CTCF is able to counteract epigenetic silencing events in the human Rb gene promoter, we decided to verify whether such a mechanism is conserved in other tumor suppressor genes, and particularly for p53 (De La RosaVela´zquez et al., 2007) . We found a putative CTCFbinding motif in a DNA fragment located at B700 bp upstream of the p53 transcription start site (Figure 3a ) (De La Rosa-Vela´zquez et al., 2007; Kim et al., 2007) . We performed a gel shift analysis using total extracts from HeLa cells to determine whether CTCF associates with this sequence in vitro (Figure 3b ). We next carried out a chromatin immunoprecipitation (ChIP) assay using an antibody against human CTCF and by using primers that flank the novel CTCF-binding sequence in several cell lines. As a negative amplification control we used the exon 27 of the Rb gene, as reported previously (De La Rosa-Vela´zquez et al., 2007) . Interestingly, we observed enrichment of the CTCF immunoprecipitated fraction in SW480 and HeLa cell lines, but not in the U87MG and T98G glioma cells lines in which p53 gene expression is silenced (Figure 3c ). We then repeated the ChIP assay by treating the T98G cells with and without 5-aza-2'-deoxycytidine and found the reincorporation of CTCF, consistent with p53 gene expression activation (Figure 3d ). It is noteworthy that in this context CTCF binding does not seem to be methylation sensitive as the CpGs present on its binding sequence are not methylated (Supplementary Figure 1, site 3) . Therefore, CTCF binding perturbation by DNA methylation is probably guided by an indirect mechanism. Together, these results confirmed CTCF association with the human p53 promoter region and its dissociation in glioma cells.
CTCF and its epigenetic role in glioma cell lines
With the aim of further assessing the role of CTCF in p53 gene regulation, we performed ChIP assays using antibodies against active and repressive histone marks in glioma cell lines (Figure 4) . We confirmed the dissociation of CTCF binding and the enrichment at the core promoter of the H4K20me3 and H3K27me3 repressive marks ( Figure 4 ). This result is not due to the depletion of CTCF, as in all the cell lines tested, including glioma cells, we observed CTCF nuclear localization by immunofluorescence assays (data not shown). This argues in favor of a local modification or displacement of CTCF by unexplored mechanisms (Figure 3d) . Surprisingly, when the DNA methylation status of the upstream sequences was analyzed in U87MG and T98G cells, we basically found no DNA methylation ( Figure 3a , sites 1-3, and data not shown). It is possible that in glioma cell lines, other and more distal genomic sequences that are DNA methylated can directly or indirectly be responsible for p53 silencing. Alternatively, we do not discard that DNA methylation is affecting the expression of a co-regulator of CTCF, such as the poly-ADP-ribosyl polymerase 1 (Yu et al., 2004 and see Discussion) . As shown, histone modifications, in (c) Chromatin immunoprecipitation assay using antibodies that recognize active and repressive histone marks. Two methylCpG-binding protein antibodies are incorporated in the study (MBD2 and MeCP2). Semi-quantitative values were determined using radioactive duplex-PCR and a representative gel is shown for each cell type (upper panel). Relative enrichment of histone covalent modifications was plotted and the fold enrichment values of at least two independent immunoprecipitations are shown. Each duplex-PCR was performed in triplicate using primers from the p53 core promoter, and standard error is presented (lower panel). For normalization we used b-actin (*) for the close histone marks and MyoD for open histone marks (**). (d) In situ restriction enzyme accessibility assay. Probe 1 corresponds to an upper band probe and Probe 2 to the opposite strand. The XbaI site is roughly located at the center of the core promoter, and StuI restriction site is used as control for complete enzymatic digestion. This is a representative Southern blot from two independent assays.
Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa particular H3K27me3, are contributing to p53 silencing in glioma cells. These results are in agreement with findings by Issa and collaborator (Kondo et al., 2008) , in which histone H3K27me3 among other repressive histone marks may have a major role in epigenetic silencing.
Functional contribution of CTCF to human p53 promoter activity To evaluate the functional contribution of CTCF to the regulation of p53 gene expression, we generated a stable HeLa knockdown cell line against CTCF (HeLa-kd-CTCF) using a small hairpin RNA (Ishihara et al., 2006) . HeLa cells were chosen because they show an intermediate level of expression, between SW480 cells and primary normal fibroblasts (Figure 1a ). In addition, HeLa cells were used in our previous analysis to show the epigenetic contribution of CTCF to human retinoblastoma gene regulation (De La Rosa-Vela´zquez et al., 2007) . Thus, CTCF knockdown will allow us to perform a comparative analysis between p53 and Rb gene expression profiles. As a control, we stably transfected HeLa cells with an empty vector and a scramble small hairpin RNA that exerts no effect on either CTCF or cellular integrity (Supplementary Figure 3) . We performed immunofluorescence and western blot assays to corroborate the reduction of CTCF levels ( Figure 5a ). We further evaluated the expression patterns of p53 using RT-PCR, and of Rb for comparison, as well as their peptide products in the CTCF knockdown cell line (Figures 5b and c) . We found a drastic reduction in the expression levels of both tumor suppressor genes. With the aim of obtaining a comparative overview of p53 gene expression profiles in the context of the CTCF knockdown cells and cells treated with 5-aza-2'-deoxycytidine and the poly(ADP-ribosyl)-polymerase inhibitor 3-aminobenzamide we determined the relative abundance of p53 mRNA (Figure 5d ). We confirmed the lack of expression in HeLa knockdown and glioma cells. 3-Aminobenzamide was incorporated to the study based on the fact that it is well established that CTCF activity can be modulated by poly(ADP-ribosyl)ation (Yu et al., 2004; Docquier et al., 2009) . Importantly, we found that poly(ADP-ribosyl)ation inhibition affects p53 gene expression probably perturbing CTCF activity. These data correlate with the notable absence of p53 and Rb proteins synthesis, and it shows the relevant role of CTCF in the regulation of two key tumor suppressor genes. Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa
Global effects of distinct histone marks in HeLa and HeLa CTCF knockdown cells Recent evidence has uncovered CTCF as an important factor involved in the maintenance of nuclear architecture (Guelen et al., 2008; Williams and Flavell, 2008) . Using immunofluorescence assays, we compared the nuclear distribution of different histone covalent modifications in HeLa and HeLa-kd-CTCF cell lines (Supplementary Figure 4) . In HeLa cells we observed an enrichment of the speckled-like pattern of H3K9me3, H3K27me3 and H4K20me3 distribution that could correspond to different heterochromatic genomic regions (Schotta et al., 2004) . However, in the CTCF knockdown cellular context, we observed a clear redistribution of heterochromatin foci. This general chromatin reorganization associated with CTCF reduction may directly or indirectly contribute to abnormal downregulation of p53 and Rb by having a role in the loss of their higher-order organization inside the nucleus.
Local chromatin structural perturbations in HeLa cells deficient in CTCF
We next analyzed the genomic sequences surrounding the CTCF-binding site and the p53 core promoter in terms of histone covalent modifications ( Figure 6 ). Concerning the chromatin structure of the most upstream area, we found an enrichment of histone H3K9me3 and H4K20me3 in HeLa knockdown cells, along with a notable diminishment of histone H3 acetylation ( Figure 6 ). Interestingly, when we focused in the core promoter, there were no changes in histone H3 acetylation, but there was a modest increase in H3K9me3, H4K20me3 and particularly H3K27me3 repressive histone marks (Figure 6 ). At this point it is worth mentioning that the histone H3K27me3 mark is exclusively found to be associated with the core p53 promoter in HeLa knockdown cells and T98G glioma cells (see Figure 4) . These results establish that the p53 promoter seems to be organized into different sub-domains in which CTCF Barski et al., 2007) . P1 represents the main p53 promoter and P2 symbolizes the alternative promoter. Below we incorporated a detailed scheme of the genomic organization of B3 kb upstream regulatory regions and first intron of the human p53 gene is also shown. Vertical lines represent CpG dinucleotides, and DNA methylation, determined by sodium bisulfite conversion in T98G glioma cells, using seven different sets of primers is shown. DNA methylation percentage of each site is plotted as a pie graph (n ¼ 8). Individual CpG sites are shown in the Supplementary Figure 1 and controls in Supplementary Figure 2. (b) A gel shift assay using total cell extracts from HeLa cells (HeLa TE) and a 75-bp labeled probe is shown. The specificity of the interaction was confirmed using the chicken cHS4 b-globin insulator CTCF-binding site and Rb-CTCF binding site as competitors and as non-specific competitor, the consensus sequence for the ubiquitous Sp1 transcription factor. The asterisk defines a nonspecific retarded complex. (c) ChIP assays were carried out on different cell lines, including the two glioma cell lines. As a negative amplification control we used primers from exon 27 of the human retinoblastoma gene (De La Rosa-Vela´zquez et al., 2007) . (d) ChIP assays were performed on T98G glioma cells, untreated (T98G mock) and treated with 5-aza-2'-deoxycytidine (5-azadC). Linear range of amplification conditions was determined using the input material (not shown). Beads and an anti-IgG were included as negative controls.
Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa seems to have a delimitating role, and that its absence induces the incorporation of differential repressive marks, such as the Polycomb-associated histone H3K27me3 mark, over the p53 core promoter.
Discussion
In this study we analyzed epigenetic events leading to the silencing of the p53 gene promoter. We propose that CTCF has a critical role in p53 gene promoter epigenetic regulation shielding the promoter against the incorporation of repressive covalent histone modifications and that the mechanisms of silencing may be, at least in part, dependent on the type of CpG island that is present. Thus, CTCF dissociation may induce dramatic and anomalous epigenetic defects leading to cancer development.
A novel aspect that emerges from our study in epithelial transformed cell lines is that the human p53 promoter seems to be in a relatively closed chromatin configuration in normal cells, and that a robust chromatin structural relaxation is associated with p53 gene expression in some tumor cell lines (Figure 1 ). This observation may suggest that in normal conditions p53 gene expression is in some way negatively regulated through epigenetic mechanisms. Therefore, to respond to different stimuli, on one hand, the p53 promoter needs to possess specific and efficient procedures to remodel its chromatin structure to enable transcription, and on the other, as clearly established, it can be regulated at the protein level (Vazquez et al., 2008; Vousden and Prives, 2009 ).
It seems that CTCF binds to tumor suppressor gene promoters, such as the p53 or Rb promoters, and more recently p16
INK4a , contributing to their epigenetic integrity (De La Rosa-Vela´zquez et al., 2007; Witcher and Emerson, 2009 ). This evidence argues in favor of the association of other factors and co-factors that cooperate with CTCF in different contexts, for example, poly(ADP-ribose) polymerase 1, brahma-related gene 1 (Su et al., 2009 ) and chromatin remodeling factors, such as histone acetyltransferases and histone methyltransferases, which counteract repressive and abnormal epigenetic signals in a coordinated manner. In contrast, the absence of one of these components, but mainly the dissociation or absence of CTCF, induces a rapid epigenetic silencing of gene promoters associated with it. Several mechanisms for CTCF dissociation can be envisioned. One possibility comes from CTCF abduction in the cytoplasm as a cause of aberrant DNA hypermethylation of the human BRCA1 gene promoter in samples from patients with sporadic breast cancer (Butcher and Rodenhiser, 2007 ). An alternative comes from DNA methylation of a sub-group of CTCFbinding motifs that possess CpG dinucleotides that, when methylated, cause CTCF dissociation (RecillasTarga et al., 2006; De La Rosa-Vela´zquez et al., 2007; Filippova, 2008) . Otherwise, it has been postulated that phosphorylation and poly(ADP-ribosyl)ation are two post-translational CTCF modifications involved in its functions (Yu et al., 2004; El-Kady and Klenova, 2005) . In agreement, poly(ADP-ribosyl)ation of CTCF has been shown to have a role in structural and functional properties at the mouse p53 locus (Su et al., 2009) . More recently, loss of CTCF binding by aberrant poly(ADPribosyl)ation is also responsible for the epigenetic Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa silencing of the p16 INK4a tumor suppressor gene (Witcher and Emerson, 2009 ). These reports are in agreement with our finding in which p53 gene expression can be altered when HeLa cells are treated with the 3-aminobenzamide inhibitor and CTCF activity is perturbed (Figure 5d ).
On the basis of our previous data and the results in this work, we propose a relationship between the nature Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa of a CpG island and the mechanism of silencing. For the retinoblastoma gene promoter, which corresponds to a high CpG island, DNA methylation is mostly involved in promoter silencing. In contrast, for the p53 promoter region formed by an intermediate CpG island, DNA methylation is not directly involved but instead H3K9me3, H4K20me3 and H3K27me3 histone modifications are the main (and probably not the only) epigenetic signals for promoter silencing. This can now be interpreted in the context of the recent chromatin structural and functional characterization of the mouse p53 locus (Su et al., 2009) . In this work, the mouse p53 locus was defined by two domains, in which the first one is shielded by sequences bound in vivo by CTCF. This domain is further depleted in histone H1, it adopts a three-dimensional organization and is enriched in open chromatin marks that extend to the promoter region and the first intron (Su et al., 2009) . Sequence analysis reveals that the human p53 genomic organization is similar to that of its mouse homolog, as it contains a second CTCF-binding site in humans (data not shown). We suggest that the genomic organization of the human p53 locus resembles its mouse homolog, and that the aberrant DNA methylation is incorporated 'outside' of the first domain, that is, upstream and downstream relative to the CTCF-binding sites, and that such distal genomic regions contribute negatively to p53 expression in glioma cell lines. An alternative interpretation of our reactivation results in glioma cells can come from the indirect effect of DNA methylation over the expression of p53 regulators or genomic loci directly or indirectly linked to p53 gene regulation. This is an attractive possibility that can even include antisense RNAs or microRNAs that merits to be explored (Le et al., 2009; Mahmoudi et al., 2009) .
Another aspect that deserves to be mentioned is the presence of a newly described p53 natural antisense transcript named Wrap53 (Mahmoudi et al., 2009) . One of its isoforms, overlapping the first exon of p53, can form Wrap53/p53 hybrids and such association has been shown to be critical for p53 normal regulation (Figure 3a) . Therefore, at this point we cannot discard that the dual location of CTCF and its potential contribution to subdomains formation can participate in the symbiotic regulation through transcriptional activation of p53 and Wrap53, and those repressive epigenetic mechanisms may be found 'outside' of this regulatory sub-domain.
An opposing player could be the paralog of CTCF, the brother of the regulator of imprinted sites (BORIS), also known as CTCFL (Klenova et al., 2002; Jelinic et al., 2006) . BORIS has been shown to be primarily expressed as a testis-specific gene (Loukinov et al., 2002) . BORIS has also shown to be abnormally expressed in a variety of cancers (Hong et al., 2005) . In a recent study on the BAG-1 oncogene promoter, it has been shown that CTCF binding to the BAG-1 gene promoter increases as the Dnmt genes are deleted, whereas BORIS binding increases when Dnmts are overexpressed . This opposing behavior is further reflected by changes in H3K4me2 and H3K9me2 ratio. Thus, we cannot discard the possibility that the hypermethylation of the Rb promoter may favor BORIS recruitment and CTCF displacement. In the case of the p53 gene promoter, BORIS incorporation seems unlikely based on the hypomethylation state of the promoter. Conversely, it has been shown, at least in vitro, that BORIS DNA binding can be methylation independent only when CTCF is displaced . Hence, BORIS binding to p53 regulatory region could also be envisioned, even in absence of DNA methylation, causing its epigenetic miss-regulation. The participation of BORIS in the epigenetic silencing of tumor suppressor genes such as Rb and p53 is a research topic that is currently under investigation. Epigenetic regulation of the p53 tumor suppressor gene E Soto-Reyes and F Recillas-Targa
Finally, we envision a structural role for CTCF in tumor suppressor gene promoters. We do not believe that CTCF is always located at the boundaries of promoter regions (Barski et al., 2007; Irizarry et al., 2009; Su et al., 2009) , and that its intergenic and/or intragenic distribution may also direct an optimal topology of each chromatin domain inside the cell nucleus. Therefore, it is attractive to consider CTCF as having a key role in tumor suppressor gene regulation, through mechanisms of action that probably occur at multiple levels.
Materials and methods

Cell culture
All the cell lines were grown in Dulbecco's modified Eagle's medium and RPMI-1640 media containing 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). The primary cell culture of fibroblasts was obtained from human neonatal foreskin tissue, and these cells were kindly provided by Luis Alonso Herrera (Instituto Nacional de Cancerologı´a, Me´xico, D.F., Me´xico), and they were grown in Dulbecco 0 s modified Eagle's medium containing 15% fetal bovine serum, 1% non-essential amino acids and 1% penicillin/streptomycin (Invitrogen).
RT-PCR
For RT-PCR analysis, total cellular RNA was isolated with Trizol reagent (Invitrogen). First-strand complementary DNA was synthesized using 1 mg of RNA per reaction with AMV reverse transcriptase and Oligo-dT (Promega, Madison, WI, USA). The primers used for RT-PCR reactions were: For p53: P53RTF2: 5 0 -GGAAGACTCCAGTGGTAATC-3 0 and P53RTR2: 5 0 -TTCAGGTGGCTGGAGTGAG-3 0 . For human glyceraldehyde-3-phosphate dehydrogenase (GAPDH): GAPDHgF: 5 0 -GGAGTCCACTGGCGTCTTC-3 0 and GAPDHgR: 5 0 -GGTTCACACCCATGACGAAC-3 0 . Rb RT-PCR was performed as described (De La RosaVela´zquez et al., 2007) . The GAPDH sequence was used as a normalizing control together with the p53 primers in a radioactive [a- 32 P]dCTP duplex PCR. The products were separated on a 5% polyacrylamide gel electrophoresis and analyzed using Image Quant 5.2 Software. The p53 expression levels were evaluated by six independent experiments.
Western blotting Cells were harvested with lysis buffer containing 20 mM HEPES pH 7.9, 400 mM potassium chloride, 20% glycerol, 2 mM dithiothreitol and protease inhibitors, and freeze-thawed twice, and proteins were quantified using the Bradford assay (Bio-Rad, Philadelphia, PA, USA). After separation using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the resolved proteins were transferred to a polyvinylidene fluoride membrane (Millipore, Milford, MA, USA). Membranes were blocked with 5% non-fat milk for 2 h and then incubated with the appropriate antibody overnight at 4 1C with anti-p53 (sc-6243) and anti-CTCF (sc-5916) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing, the blots were incubated for 1 h with an appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology), and washed and then detected with a chemiluminescence substrate according to the manufacturer's instructions (Pierce, Rockford, IL, USA).
ChIP assay
The ChIP assay was performed as previously reported (ValadezGraham et al., 2004) with 4 mg of antibodies against acH3, acH4 and H3K4me2 antibodies from Upstate (Billerica, MA, USA) and H3K9me3, H3K27me3 and H4K20me3 antibodies kindly provided by Thomas Jenuwein (Max-Planck Institute of Immunobiology, Freiburg, Germany). Immunoprecipitated DNA was analyzed by PCR using primers specific for the human p53 gene promoter. For the semi-quantitative ChIP assay, duplex-PCR was performed as described (Sawado et al., 2001) . Primer sequences used for ChIP assays are available by request. For the duplex PCR we used for normalization b-actin for the close histone marks and MyoD for open histone marks (Sawado et al., 2001) . For each antibody, at least three independent ChIP experiments were performed.
Restriction enzyme accessibility assay For restriction endonuclease in situ nuclear digestion we followed the protocol established previously (Escamilla-DelArenal and Recillas-Targa, 2008). Data were analyzed using Southern blotting with EcoRI genomic restriction enzyme digestion. Two complementary probes were used (probes 1 and 2).
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay and nuclear extract preparation were performed as previously described (Schreiber et al., 1989; Valadez-Graham et al., 2004) . Competitions were carried out with 200 pmol of gel-purified unlabeled oligonucleotides. The probes used (showing only the top strand) were P53CTCF F: 5 0 -CCTACGCTCCCCCTACCGAGTCCCGC GGTAATTCTTAAAGCACCTGCACCGCCCCCCCGCCG CCTGCAGAGGGCG-3 0 . FII (CTCF-binding site of the chicken b-globin cHS4 insulator), Rb-CTCF motif and Sp1 primers were used as competitors (De La Rosa-Vela´zquez et al., 2007) .
DNA methylation analysis
Bisulfite analysis was performed as previously described (Clark et al., 2006) ; the sequences of the primers used for amplification of the bisulfite-treated promoter are shown in the Supplementary Table 1. A second round of PCR amplification was performed using nested sets of primers (Kang et al., 2001) . The DNA from the second PCR was gel purified, and amplification products were cloned in pGEM-T Easy vector (Promega) for sequencing using the T7 primer. A DNA fragment including 16 CpG dinucleotides of the p53 core promoter and neighboring genomic sequences (sites 1-7) were amplified and sequenced in T98G cells and different cell lines (for sites 3 and 4). As controls, DNA from normal human lymphocytes was methylated in vitro by SssI methyltransferase, and used as a positive methylated DNA from an Alu repeat and the promoter region of the FZD9 gene (see Supplementary  Table 1 ). Bisulfite genomic-sequencing primers were designed using Methyl Primer Express Software (Applied Biosystems, Foster City, CA, USA).
Stable transfection of small hairpin RNA against CTCF in HeLa cells HeLa cells were stably transfected using LipofectAMINE 2000 (Invitrogen) with an small hairpin RNA expression vector targeting CTCF (pCT1) kindly provided by Ko Ishihara (Institute of Molecular Embryology and Genetics, Kumamoto University, Japan) (Ishihara et al., 2006) . HeLa cells were selected for 3 weeks in the presence of puromycin (1 mg/ml).
